Pelthos Therapeutics Inc. (PTHS) is a Healthcare stock trading at $27.50 (as of 2026-06-18), with a market capitalization of $92.00M and a trailing P/E of -1.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.